Ob/Gyn Medical News about Breast Neoplasms Risk

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 09/15/09

Nelson HD et al. – Three medications reduce risk for primary breast cancer but increase risk for thromboembolic events (tamoxifen, raloxifene), endometrial cancer (tamoxifen), or stroke (tibolone).

Methods

MEDLINE and Cochrane databases from inception to January 2009, Web of Science, trial registries, and manufacturer information were searched. English–language reports of randomized, controlled trials (RCTs) for benefits and RCTs and observational studies for harms were included.
Two reviewers assessed study data, quality, and applicability.

Results

Seven placebo–controlled RCTs and 1 head–to–head trial provide results for main outcomes.
Tamoxifen, raloxifene, and tibolone reduce risk for invasive breast cancer compared with placebo by 7 to 10/1000 women per year.
Tamoxifen and raloxifene reduce estrogen receptor–positive breast cancer, but not estrogen receptor–negative breast cancer, noninvasive breast cancer, or mortality; all medications reduce fractures.
Tamoxifen and raloxifene increase thromboembolic events by 4 to 7/1000 women per year; raloxifene causes fewer events than tamoxifen.
Tamoxifen increases risk for endometrial cancer compared with placebo by 4/1000 women per year and causes cataracts compared with raloxifene.
Tibolone causes strokes in older women.

<< Previous
Uric acid concentrations are associated with insulin resistance...

Next >>
Cutaneous metastases from carcinoma breast: The common and the...

Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09 Relevance Score: 82%

Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk
American Journal of Epidemiology, 10/22/09 Relevance Score: 82%

Postmenopausal Breast Cancer Risk and Dietary Patterns in the E3N-EPIC Prospective Cohort Study
American Journal of Epidemiology, 10/22/09 Relevance Score: 82%

Evidence-based care for breast cancer survivors: Communicating the Institute of Medicine Guidelines in medical practice
Patient Education and Counselling, 11/04/09 Relevance Score: 81%

Mammographic Screening and Risk Factors for Breast Cancer
American Journal of Epidemiology, 10/30/09 Relevance Score: 81%